Axitinib, an inhibitor of VEGFR-1, 2, and 3, increased the number of naïve CD8+ T cells and central memory CD4+ and CD8+ T cells and reduced T-reg expression, leading to better antitumor immune responses in patients with recurrent GBM [41]. The gene discussed is CD8A; the disease is glioblastoma.